SCHEMBL4575476

SCHEMBL4575476

NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)C1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.69
DPP4 P27487 6/20 0.68
CHRM2 P08172 2/20 0.63
ALDH1A1 P00352 2/20 0.63
POLB P06746 1/20 0.63
CHRM1 P11229 1/20 0.63
OPRM1 P35372 1/20 0.63
OPRD1 P41143 1/20 0.63
DRD1 P21728 1/20 0.60
LMNA P02545 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HSD17B10 Q99714 2/20 0.56
ABCC4 O15439 1/20 0.56
DHFR P00374 1/20 0.53
EPHA2 P29317 1/20 0.52
FLT4 P35916 1/20 0.52
GSK3B P49841 1/20 0.52
RARB P10826 1/20 0.52
TBXAS1 P24557 1/20 0.52
SLC6A3 Q01959 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9838735 1.00 KMT2A (0.69) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL13576371 1.00 KMT2A (0.69) KMT2ADPP4CHRM2ALDH1A1POLB
Hydrochloric Acid SCHEMBL10652931 0.99 KMT2A (0.68) KMT2ADPP4CHRM2ALDH1A1POLB
Hydrochloric Acid SCHEMBL10824865 0.95 KMT2A (0.66) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL11022634 0.94 DPP4 (0.68) KMT2ADPP4CHRM2ALDH1A1POLB
Hydrochloric Acid SCHEMBL20394712 0.93 DPP4 (0.67) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL9177508 0.89 DPP4 (0.65) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL9177523 0.89 DPP4 (0.65) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL9177514 0.89 DPP4 (0.65) KMT2ADPP4CHRM2ALDH1A1POLB
SCHEMBL10928412 0.89 DPP4 (0.64) KMT2ADPP4CHRM2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1305048-A2 INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES Wockhardt Limited (IN) 2003-05-02 EP claimed
US-20020177559-A1 Quinolone derivatives WOCKHARDT LIMITED 2002-11-28 US claimed
WO-2002009758-A2 INHIBITORS OF CELLULAR EFFLUX PUMPS OF MICROBES WOCKHARDT LIMITED (IN) 2002-02-07 WO claimed
EP-0235589-B1 USE OF QUINOLONE AND NAPHTHYRIDINE ANTIBIOTICS FOR THE MANUFACTURE OF OPHTHALMIC MEDICAMENTS WARNER-LAMBERT COMPANY (US) 1992-10-28 EP claimed
EP-0394685-A2 (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid WARNER-LAMBERT COMPANY (US) 1990-10-31 EP claimed
US-4916141-A ANTIBACTERIAL WARNER-LAMBERT COMPANY (US) 1990-04-10 US claimed
US-4851415-A TOPICAL ADMINISTRATION WARNER-LAMBERT COMPANY (US) 1989-07-25 US claimed
EP-0235589-A2 Use of quinolone and naphthyridine antibiotics for the manufacture of ophthalmic medicaments WARNER-LAMBERT COMPANY (US) 1987-09-09 EP claimed
US-4649144-A Antibacterial 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid derivatives DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1987-03-10 US claimed
EP-0187376-A2 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids BAYER AG (DE) 1986-07-16 EP claimed
EP-0153163-A2 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds WARNER-LAMBERT COMPANY (US) 1985-08-28 EP claimed
EP-0132845-A2 Novel 1,8-Naphthyridine derivatives, and process for preparation thereof Dainippon Pharmaceutical Co., Ltd. (JP) 1985-02-13 EP claimed
JP-60028978-A None JP disclosed
JP-2289568-A None JP disclosed
US-20250295790-A1 LECTIN-TARGETING CONJUGATES HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-09-25 US disclosed
EP-4444355-A2 LECTIN-TARGETING CONJUGATES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-10-16 EP disclosed
EP-0160578-A1 1,8-Naphthyridine derivatives DAIICHI SEIYAKU CO., LTD. (JP) 1985-11-06 EP disclosed
EP-0153163-A2 7-Substituted-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids; 7-substituted-1-cyclopropyl-1,4-dihydro-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acids; their derivatives; and a process for preparing the compounds WARNER-LAMBERT COMPANY (US) 1985-08-28 EP disclosed
JP-S6028978-A 1,8-NAPHTHYRIDINE DERIVATIVE DAINIPPON PHARMACEUT CO LTD 1985-02-14 JP disclosed
EP-0132845-A2 Novel 1,8-Naphthyridine derivatives, and process for preparation thereof Dainippon Pharmaceutical Co., Ltd. (JP) 1985-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295790-A1 LECTIN-TARGETING CONJUGATES MASP2, LGALS3BP, LGALS1 KMT2A 4324/4885DPP4 161/4885CHRM2 3211/4885
US-20020177559-A1 Quinolone derivatives ABCB11, ABCB1, ABCG2 KMT2A 4343/4885DPP4 819/4885CHRM2 4526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.